Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | TNKS | O95271 | 4/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 4/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.37 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29142195 | 0.83 | PARP1 (0.36) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL22028973 | 0.78 | PARP1 (0.36) | PARP1PIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL22393820 | 0.78 | PKM (0.46) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL22101792 | 0.78 | PIM1 (0.38) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL30826848 | 0.78 | PARP1 (0.36) | PARP1PIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL22101365 | 0.76 | PARP1 (0.47) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL22393695 | 0.76 | PARP2 (0.38) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL22101861 | 0.75 | PARP1 (0.42) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL22101758 | 0.75 | CDC7 (0.47) | PARP1TNKSTNKS2PIM1CSNK2B | |
| SCHEMBL577862 | 0.75 | PARP1 (0.51) | PARP1TNKSTNKS2PARP2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | PARP1 3854/4885TNKS 2033/4885TNKS2 1465/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | PARP1 3854/4885TNKS 2033/4885TNKS2 1465/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | PARP1 3854/4885TNKS 2033/4885TNKS2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.